Inhibitors of the PI3K/Akt/mTOR pathway may be effective against PPC with PIK3CA mutations, because chemotherapy-resistant cell lines are reported to be sensitive to PI3K inhibitors [31]. Here, MTOR is linked to primary peritoneal carcinoma.